About Inova Labs

John Rush

John Rush has more than 28 years of experience in the medical device sector, and joined Inova Labs as Chief Executive Officer in 2011. Previously, Rush served as Chief Executive Officer of U.K. – based Lombard Medical Technologies PLC, a medical device company for the abdominal aortic aneurysm repair market, from 2009 to early 2011. Currently, Rush also serves as non-executive Chairman of the Lombard Medical Board of Directors. During his tenure at Lombard, the Company successfully navigated through an IDE PMA trial in the United States which led to FDA approval for it’s AAA stent graft in early 2013. Before joining Lombard, Rush was President and CEO of North American Scientific, Inc. (NASDAQ: NASM) where he re-organized the company and led an investor group initiative to take part of the company private. Rush also served as President and CEO of MicroTherapeutics, Inc. (NASDAQ:MTIX), an interventional neuroradiology company with operations in the United States and Europe. He orchestrated a successful sale of the company to ev3. Prior to MTIX, Rush spent 10 years with Scimed Life Systems/Boston Scientific in various management roles, including General Manager of Boston Scientific’s Asia Pacific business based in Singapore. Rush has extensive domestic and international experience, with a core sales and marketing background.

Barry Thwaits

Barry Thwaits brings 26 years of experience in the medical industry to his role as VP of International Sales at Inova Labs.   Previously, Thwaits was employed at Philips Respironics where he worked in both the critical care market as well as the home health market.  During his tenure at Philips Respironics, he held positions in sales management in North America as well as sales and marketing management in international markets.  Prior to joining Inova Labs, Thwaits served as a business leader for a 50 million dollar business in his role as Markets Manager Latin America for Philips Respironics Home Health Solutions.  Prior to that role, he managed a 450 million dollar budget as a VP of Sales in North America where he had responsibility for sales to strategic accounts in the Home Health Industry. He also has extensive experience working in Europe and the Middle East in both the Home Health Care and Critical Care Markets.

Thwaits holds a degree in Political Science from Arizona State University.

Mark Wan

Mark Wan is a co-founding Partner of Causeway Media Partners, an investment firm focused on sports media and content. He is also a co-founding partner of Three Arch Partners, a healthcare focused investment firm and has been a founder or seed investor in numerous healthcare companies including Ascend Health, Epocrates, and Odyssey Healthcare.

Wan has a BS in Engineering and a BA in Economics from Yale University and has an MBA from Stanford.

Ron Yarbrough

Ron Yarbrough joined Inova Labs as Vice President of RAQA in July of 2013. Prior to joining Inova Labs, Yarbrough served as Director of Regulatory Affairs and prior to that as Director of Quality Assurance for Zimmer Spine based in Minneapolis, MN. He has held a variety of positions with increasing responsibility at Zimmer Spine, Abbott Laboratories, Zimmer Orthopedics, Centerpulse, Sulzer, and Intermedics and worked in a variety of functions, including Product Development, Operations, Quality Assurance, and Regulatory Affairs management.

Yarbrough has over 15 years of extensive experience in the medical device industry dealing with a variety of Class I, II, and III products, as well as tissue banking. He has created and executed strategies to obtain predictable global product approvals and significantly improve product quality by implementing enhanced design controls and advanced production/process controls. Rising quickly from a top technical contributor to a position as divisional Director of Quality Assurance and then Regulatory Affairs, Yarbrough’s organizations led companies to establish world-class quality systems and successfully resolve chronic problems. Yarbrough is responsible for all global regulatory and quality activities and functions as the management representative for Inova Labs.

Yarbrough holds a Bachelor of Science degree in Industrial Technology from Texas State University.

Phil Martin

Phil Martin has over 30 years of experience in the medical device industry. Prior to joining Inova Labs in 2011, Martin served as Vice President of Sales Interventional Cardiology for Boston Scientific from 2003 to 2010. He also served Boston Scientific as Director of Sales from 1994 to 2003. Prior to his experience with Boston Scientific, Martin spent over 10 years in Sales and Marketing at Johnson & Johnson.

Martin holds a Bachelor of Science degree in Business Management from Alfred University.

Rod Young

Rod Young joined Three Arch Partners as a Venture Partner in May 2006. Prior to Three Arch Partners, Young was President and CEO of Vivant Medical, a Three Arch Partners medical device company that was acquired by Tyco, President & CEO of Targesome, Chairman & CEO of General Surgical Innovations, also a Three Arch Partners medical device company that was acquired by Tyco, President & CEO of Focus Surgery, President of Toshiba America MRI, and President & COO of Diasonics.

Young holds a BS degree in Industrial Engineering from Stanford University and an MBA from the Harvard Business School.

Geoff Pardo

Geoff Pardo joined Gilde in 2011 as a Partner and is responsible for Gilde’s US office in Boston/Cambridge, MA and for investments in North America. He led the investment in Inova Labs and represents Gilde as a member of its board of directors. Previously, Pardo was a Partner at Spray Venture Partners where he led investments into Interlace Medical (sold to Hologic), Solace Therapeutics, TearScience and Cascade Ophthalmics. He served on the board of Solace, TearScience and Cascade, and was actively involved in Interlace and Conventus Orthopedics. He also served as President and CEO of Facet Solutions, a spinal implant company focused on treating lumbar spinal stenosis until the company was sold to Globus Medical in 2011. Pardo worked at Cardinal Partners as an Associate leading their investing activity in the medical device sector. He was responsible for sourcing and managing investments in Replication Medical and CardioOptics. Pardo began his career in medical devices as a product manager with Synthes USA. While there, he led the market introduction of a bone graft substitute which was named Synthes’ impact product of the year in 1999.

Pardo has a B.A. with honors in History from Brown University and an M.B.A. from the Wharton School of Business.

Steve Salmon

Stephen Salmon is a seasoned medical device professional bringing over 20 years of product development and management experience to LVP. Salmon has held several executive and R&D management positions within both large public medical device companies and small medical device startups, including Engineering Manager with CVIS (acquired by Boston Scientific), VP R&D with Boston Scientific, Co-Founder and VP Operations of Integrated Vascular Systems (acquired by Abbott), and Co-Founder of Ensure Medical (acquired by JNJ). His device experience is broad, spanning products in interventional cardiology, neurovascular, peripheral vascular, gastrointestinal, orthopedic, cardiac and vascular surgery.

During his tenure in the medical device industry, Salmon has authored or co-authored 18 U.S. patents, with several additional patents pending. Salmon holds a B.S. in Chemical Engineering from the University of Maine.

Dennis Meteny

Dennis Meteny spent fifteen years with Respironics, Inc., where he began as Vice President and CFO in 1984 before becoming the President and CEO from 1994 to 1999.  During his tenure, Respironics grew from $1 million in annual revenue to more than $400 million.  Meteny has also held the position of President and a member of the Board of Directors of Cygnus Manufacturing Company (“CMC”), a manufacturing services company servicing the medical device, energy, aerospace and transportation markets.  In addition, he was also a former Executive in Residence with The Pittsburgh Life Sciences Greenhouse and the former President and Board Member of Tissue Informatics Inc., a venture capital backed company in the medical imaging sector.  Meteny currently serves as Non-Executive Director and Audit Committee Chairman for Angiodynamics, Inc., and as a Director of Blue Water Growth, a global business consulting firm.

Metney holds a Bachelor of Science degree in Accounting from Pennsylvania State University and an MBA from the University of Pittsburgh Katz School of Business.

Dr. Dragan Nebrigic

In January 2013, Dr. Dragan Nebrigic was appointed Chief Technology Officer at Inova Labs where he had held the position of Vice President of Product Development since February 2012. Dr. Nebrigic brings to Inova Labs more than 20 years of experience in medical devices and biotechnologies. He holds over 40 US and International Patents in the area of medical devices, consumer electronics and medical sensor technologies.

Prior to working at Inova Labs, Dr. Nebrigic served as Vice President of Research and Development with Thermage, as well as Vice President of Research and Development with Solta Medical. He also held the position of Senior Director of Global Advanced Technologies and Intellectual Property with Maxwell Technologies and served as the Executive Director of Engineering and Advanced Technologies with the American Technology Corporation and Molecular Reflections Corporation. During his tenure with Procter and Gamble from 1996 until 2000, Dr. Nebrigic spearheaded efforts related to novel portable energy sources as well as new consumer biosensor and portable medical devices applications. He also held an adjunct Professor position of Electrical Engineering with the University of Cincinnati.

Dr. Nebrigic holds a M.S. in Electrical and Computer Engineering and Technical Physics from the University of Belgrade Serbia and Ph.D. in Electrical and Computer Engineering from the University of Cincinnati.